Last reviewed · How we verify
Colon- Closed as of May 2014
Colon- Closed as of May 2014 is a Small molecule drug developed by howard safran. It is currently in Phase 1 development.
At a glance
| Generic name | Colon- Closed as of May 2014 |
|---|---|
| Sponsor | howard safran |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Colon- Closed as of May 2014 CI brief — competitive landscape report
- Colon- Closed as of May 2014 updates RSS · CI watch RSS
- howard safran portfolio CI
Frequently asked questions about Colon- Closed as of May 2014
What is Colon- Closed as of May 2014?
Colon- Closed as of May 2014 is a Small molecule drug developed by howard safran.
Who makes Colon- Closed as of May 2014?
Colon- Closed as of May 2014 is developed by howard safran (see full howard safran pipeline at /company/howard-safran).
What development phase is Colon- Closed as of May 2014 in?
Colon- Closed as of May 2014 is in Phase 1.
Related
- Manufacturer: howard safran — full pipeline
- Compare: Colon- Closed as of May 2014 vs similar drugs
- Pricing: Colon- Closed as of May 2014 cost, discount & access